Eli Lilly And Company (LLY) Partners With OpenAI To Create “Novel Antimicrobials” For Drug-Resistant Pathogens

After successfully leveraging the ongoing craze around weight loss drugs that leverage a GLP-1 agonist to offer better efficacy, Eli Lilly and Company (LLY) seems to have turned its gaze toward combating drug-resistant pathogens. What's more, the pharma giant has partnered with one of the biggest AI names for this endeavor. To wit, Eli Lilly and Company has announced that it is partnering with OpenAI to create "novel antimicrobials" for drug-resistant pathogens. Antimicrobial Resistance (AMR) is a particularly grave concern in low- and middle-income countries, where the excessive use of antimicrobials and antibiotics in humans, animals, and plants is giving […]

Read full article at https://wccftech.com/eli-lilly-and-company-lly-partners-with-openai-to-create-novel-antimicrobials-for-drug-resistant-pathogens/